• 1  Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010;10(10):70719.Cross Ref linkPubmed link
  • 2  Rabkin CS, Janz S, Lash A, et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 1997;336(14):98893.Cross Ref linkPubmed link
  • 3  Cancian L, Hansen A, Boshoff C. Cellular origin of Kaposi's sarcoma and Kaposi's sarcoma‐associated herpesvirus‐induced cell reprogramming. Trends Cell Biol 2013;23(9):42132.Cross Ref linkPubmed link
  • 4  Dal Maso L, Polesel J, Ascoli V, et al. Classic Kaposi's sarcoma in Italy, 1985–1998. Br J Cancer 2005;92(1):18893.Cross Ref linkPubmed link
  • 5  Vitale F, Briffa DV, Whitby D, et al. Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. Int J Cancer 2001;91(4):58891.Cross Ref linkPubmed link
  • 6  Geddes M, Franceschi S, Barchielli A, et al. Kaposi's sarcoma in Italy before and after the AIDS epidemic. Br J Cancer 1994;69(2):3336.Cross Ref linkPubmed link
  • 7  Atzori L, Fadda D, Ferreli C, et al. Classic Kaposi's sarcoma in southern Sardinia, Italy. Br J Cancer 2004;91(7):12612.Cross Ref linkPubmed link
  • 8  Ascoli V, Zambon P, Manno D, et al. Variability in the incidence of classic Kaposi's sarcoma in the Veneto region, northern Italy. Tumori 2003;89(2):1224.Pubmed link
  • 9  Stratigos JD, Katoulis AC, Stavrianeas NG. An overview of classic Kaposi's sarcoma in Greece. Adv Exp Med Biol 1999;455:5036.Cross Ref linkPubmed link
  • 10  Stratigos JD, Potouridou I, Katoulis AC, et al. Classic Kaposi's sarcoma in Greece: a clinico‐epidemiological profile. Int J Dermatol 1997;36(10):73540.Cross Ref linkPubmed link
  • 11  Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. Molecular genetics of Kaposi's sarcoma‐associated herpesvirus (human herpesvirus‐8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 2003;67(2):175212, table of contents.Cross Ref linkPubmed link
  • 12  Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002;2(6):34452.Cross Ref linkPubmed link
  • 13  Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002;2(5):28192.Cross Ref linkPubmed link
  • 14  Athale UH, Patil PS, Chintu C, Elem B. Influence of HIV epidemic on the incidence of Kaposi's sarcoma in Zambian children. J Acquir Immune Defic Syndr 1995;8(1):96100.
  • 15  Lothe F. Kaposi's sarcoma in Uganda Africans. Acta Pathol Microbiol Scand 1963:161(Suppl.):171.
  • 16  Thijs A. L'angiosarcomatose de Kaposi au Congo belge et au Ruanda‐Urundi. [Kaposi's angiosarcomatosis in the Belgian Congo and Ruanda‐Urundi.] Ann Soc Belg Med Trop (1920) 1957;37(2):295308.
  • 17  Serwadda D, Carswell W, Ayuko WO, Wamukota W, Madda P, Downing RG. Further experience with Kaposi's sarcoma in Uganda. Br J Cancer 1986;53(4):497500.Cross Ref linkPubmed link
  • 18  Phillips JI, Sher R. Kaposi's sarcoma in different populations in South Africa. S Afr Med J 1987;71(10):61519.Pubmed link
  • 19  Stein ME, Spencer D, Ruff P, Lakier R, MacPhail P, Bezwoda WR. Endemic African Kaposi's sarcoma: clinical and therapeutic implications. 10‐year experience in the Johannesburg Hospital (1980–1990). Oncology 1994;51(1):639.Cross Ref linkPubmed link
  • 20  Ziegler J, Newton R, Bourboulia D, et al. Risk factors for Kaposi's sarcoma: a case‐control study of HIV‐seronegative people in Uganda. Int J Cancer 2003;103(2):23340.Cross Ref linkPubmed link
  • 21  Nihal M, Mikkola D, Qian Z, Remick SC, Wood GS. The clonality of tumor‐infiltrating lymphocytes in African Kaposi's sarcoma. J Cutan Pathol 2001;28(4):2005.Cross Ref linkPubmed link
  • 22  Schwartz EJ, Dorfman RF, Kohler S. Human herpesvirus‐8 latent nuclear antigen‐1 expression in endemic Kaposi sarcoma: an immunohistochemical study of 16 cases. Am J Surg Pathol 2003;27(12):154650.Cross Ref linkPubmed link
  • 23  Farge D. Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med 1993;2(6):33943.Pubmed link
  • 24  Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997;64(5):66973.Cross Ref linkPubmed link
  • 25  Penn I. Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation 1979;27(1):811.Cross Ref linkPubmed link
  • 26  Montagnino G, Bencini PL, Tarantino A, Caputo R, Ponticelli C. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am J Nephrol 1994;14(2):1216.Cross Ref linkPubmed link
  • 27  Pedagogos E, Nicholls K, Dowling J, Becker G. Kaposi's sarcoma post renal transplantation. Aust NZ J Med 1994;24(6):7223.Cross Ref link
  • 28  Frances C, Farge D, Desruennes M, Boisnic S. Maladie de Kaposi des transplantes cardiaques. [Kaposi's sarcoma in after heart transplantation.] Ann Dermatol Venereol 1991;118(11):8646.Pubmed link
  • 29  Qunibi W, Al‐Furayh O, Almeshari K, et al. Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. Transplantation 1998;65(4):5835.Cross Ref linkPubmed link
  • 30  Zavos G, Bokos J, Papaconstantinou I, et al. Clinicopathological aspects of 18 Kaposi's sarcoma among 1055 Greek renal transplant recipients. Artif Organs 2004;28(6):5959.Cross Ref linkPubmed link
  • 31  Tessari G, Naldi L, Boschiero L, et al. Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. Eur J Dermatol 2006;16(5):5537.Pubmed link
  • 32  Alzahrani AJ, El‐Harith el HA, Milzer J, et al. Increased seroprevalence of human herpes virus‐8 in renal transplant recipients in Saudi Arabia. Nephrol Dial Transplant 2005;20(11):25326.Cross Ref linkPubmed link
  • 33  Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000;27(4):390401.Pubmed link
  • 34  Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. Aids 2003;17(11):F1722.Cross Ref linkPubmed link
  • 35  Martin JN, Ganem DE, Osmond DH, Page‐Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998;338(14):94854.Cross Ref linkPubmed link
  • 36  Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol 2008;59(2):179206; quiz 7–8.Cross Ref linkPubmed link
  • 37  Dezube BJ. AIDS‐related Kaposi sarcoma: the role of local therapy for a systemic disease. Arch Dermatol 2000;136(12):15546.Pubmed link
  • 38  Gallo RC. The enigmas of Kaposi's sarcoma. Science 1998;282(5395):18379.Cross Ref linkPubmed link
  • 39  Kao GF, Johnson FB, Sulica VI. The nature of hyaline (eosinophilic) globules and vascular slits of Kaposi's sarcoma. Am J Dermatopathol 1990;12(3):25667.Cross Ref linkPubmed link
  • 40  Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H‐ and Y‐antigens – evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994;7(1):8290.Pubmed link
  • 41  DeYoung BR, Swanson PE, Argenyi ZB, et al. CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. J Cutan Pathol 1995;22(3):21522.Cross Ref linkPubmed link
  • 42  Debelenko LV, Perez‐Atayde AR, Mulliken JB, Liang MG, Archibald TH, Kozakewich HP. D2‐40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. Mod Pathol 2005;18(11):145460.Cross Ref linkPubmed link
  • 43  Fukunaga M. Expression of D2‐40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 2005;46(4):396402.Cross Ref linkPubmed link
  • 44  Cheuk W, Wong KO, Wong CS, Dinkel JE, Ben‐Dor D, Chan JK. Immunostaining for human herpesvirus 8 latent nuclear antigen‐1 helps distinguish Kaposi sarcoma from its mimickers. Am J Clin Pathol 2004;121(3):33542.Cross Ref linkPubmed link
  • 45  Hong A, Davies S, Lee CS. Immunohistochemical detection of the human herpes virus 8 (HHV8) latent nuclear antigen‐1 in Kaposi's sarcoma. Pathology 2003;35(5):44850.Cross Ref linkPubmed link
  • 46  Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus‐like DNA sequences in AIDS‐associated Kaposi's sarcoma. Science 1994;266(5192):18659.Cross Ref linkPubmed link
  • 47  He J, Bhat G, Kankasa C, et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother‐child pairs with KS. J Infect Dis 1998;178(6):178790.Cross Ref linkPubmed link
  • 48  Davidovici B, Karakis I, Bourboulia D, et al. Seroepidemiology and molecular epidemiology of Kaposi's sarcoma‐associated herpesvirus among Jewish population groups in Israel. J Natl Cancer Inst 2001;93(3):194202.Cross Ref linkPubmed link
  • 49  Pauk J, Huang ML, Brodie SJ, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000;343(19):136977.Cross Ref linkPubmed link
  • 50  Friborg J, Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402(6764):88994.Pubmed link
  • 51  Si H, Robertson ES. Kaposi's sarcoma‐associated herpesvirus‐encoded latency‐associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol 2006;80(2):697709.Cross Ref linkPubmed link
  • 52  Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma‐associated herpesvirus targets the retinoblastoma‐E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6(10):11217.Cross Ref linkPubmed link
  • 53  Godden‐Kent D, Talbot SJ, Boshoff C, et al. The cyclin encoded by Kaposi's sarcoma‐associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol 1997;71(6):41938.Pubmed link
  • 54  Ojala PM, Tiainen M, Salven P, et al. Kaposi's sarcoma‐associated herpesvirus‐encoded v‐cyclin triggers apoptosis in cells with high levels of cyclin‐dependent kinase 6. Cancer Res 1999;59(19):49849.Pubmed link
  • 55  Ojala PM, Yamamoto K, Castanos‐Velez E, Biberfeld P, Korsmeyer SJ, Makela TP. The apoptotic v‐cyclin‐CDK6 complex phosphorylates and inactivates Bcl‐2. Nat Cell Biol 2000;2(11):81925.Cross Ref linkPubmed link
  • 56  Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. The human herpes virus 8‐encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 2002;277(16):1374551.Cross Ref linkPubmed link
  • 57  Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. Kaposi's sarcoma‐associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci USA 2005;102(15):55705.Cross Ref linkPubmed link
  • 58  Ruocco E, Ruocco V, Tornesello ML, Gambardella A, Wolf R, Buonaguro FM. Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol 2013;31(4):41322.Cross Ref linkPubmed link
  • 59  Wang HW, Trotter MW, Lagos D, et al. Kaposi sarcoma herpesvirus‐induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004;36(7):68793.Cross Ref linkPubmed link
  • 60  Morris VA, Punjabi AS, Wells RC, Wittkopp CJ, Vart R, Lagunoff M. The KSHV viral IL‐6 homolog is sufficient to induce blood to lymphatic endothelial cell differentiation. Virology 2012;428(2):11220.Cross Ref linkPubmed link
  • 61  Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma‐associated herpesvirus. Nat Genet 2004;36(7):6835.Cross Ref linkPubmed link
  • 62  Carroll PA, Brazeau E, Lagunoff M. Kaposi's sarcoma‐associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 2004;328(1):718.Cross Ref linkPubmed link
  • 63  Byun M, Ma CS, Akcay A, et al. Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med 2013;210(9):174359.Cross Ref linkPubmed link
  • 64  Montesu MA, De Marco R, Cottoni F. Soil silicates and Kaposi's sarcoma in Sardinia. Lancet 1995;346(8987):14367.Cross Ref linkPubmed link
  • 65  Ziegler JL. Endemic Kaposi's sarcoma in Africa and local volcanic soils. Lancet 1993;342(8883):134851.Cross Ref linkPubmed link
  • 66  Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993;28(3):37195.Cross Ref linkPubmed link
  • 67  Schwartz RA, Burgess GH, Hoshaw RA. Patch stage Kaposi's sarcoma. J Am Acad Dermatol 1980;2(6):50912.Cross Ref linkPubmed link
  • 68  Buchbinder A, Friedman‐Kien AE. Clinical aspects of Kaposi's sarcoma. Curr Opin Oncol 1992;4(5):86774.Cross Ref linkPubmed link
  • 69  Wabinga HR, Parkin DM, Wabwire‐Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989–91: changes in incidence in the era of AIDS. Int J Cancer 1993;54(1):2636.Cross Ref linkPubmed link
  • 70  Slavin G, Cameron HM, Forbes C, Mitchell RM. Kaposi's sarcoma in East African children: a report of 51 cases. J Pathol 1970;100(3):18799.Cross Ref linkPubmed link
  • 71  Buchbinder A, Friedman‐Kien AE. Clinical aspects of epidemic Kaposi's sarcoma. Cancer Surv 1991;10:3952.Pubmed link
  • 72  Volberding PA. Kaposi's sarcoma and the acquired immunodeficiency syndrome. Med Clin N Am 1986;70(3):66575.Pubmed link
  • 73  Medeiros S, Coelho R, Fernandes C, et al. Leprosy and Kaposi sarcoma presenting as an immune reconstitution inflammatory syndrome in a patient with AIDS. J Am Acad Dermatol 2009;61(3):51618.Cross Ref linkPubmed link
  • 74  Papagatsia Z, Jones J, Morgan P, Tappuni AR. Oral Kaposi sarcoma: a case of immune reconstitution inflammatory syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108(1):705.Cross Ref linkPubmed link
  • 75  Krown SE, Testa MA, Huang J. AIDS‐related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997;15(9):308592.Pubmed link
  • 76  El Amari EB, Toutous‐Trellu L, Gayet‐Ageron A, et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. Aids 2008;22(9):101928.Cross Ref linkPubmed link
  • 77  Nasti G, Talamini R, Antinori A, et al. AIDS‐related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART era – the Italian Cooperative Group on AIDS and Tumors and the Italian cohort of patients naive from antiretrovirals. J Clin Oncol 2003;21(15):287682.Cross Ref linkPubmed link
  • 78  Bower M, Dalla Pria A, Coyle C, et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. J Clin Oncol 2014;32(5):40914.Cross Ref linkPubmed link
  • 79  Mitsuyasu RT. Clinical variants and staging of Kaposi's sarcoma. Semin Oncol 1987;14(2 Suppl. 3):1318.Pubmed link
  • 80  Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol 2003;13(1):836.Pubmed link
  • 81  Krigel RL, Laubenstein LJ, Muggia FM. Kaposi's sarcoma: a new staging classification. Cancer Treat Rep 1983;67(6):5314.Pubmed link
  • 82  Volberding PA. Moving towards a uniform staging for human immunodeficiency virus‐associated Kaposi's sarcoma. J Clin Oncol 1989;7(9):11845.Pubmed link
  • 83  Liu W, Lacouture ME, Jiang J, et al. KSHV/HHV8‐associated primary cutaneous plasmablastic lymphoma in a patient with Castleman's disease and Kaposi's sarcoma. J Cutan Pathol 2006;33(Suppl. 2):4651.Cross Ref linkPubmed link
  • 84  Carbone A. KSHV/HHV‐8 associated Kaposi's sarcoma in lymph nodes concurrent with Epstein‐Barr virus associated Hodgkin lymphoma. J Clin Pathol 2005;58(6):6268.Cross Ref linkPubmed link
  • 85  Carbone A, Gloghini A, Vaccher E, et al. Kaposi's sarcoma‐associated herpesvirus/human herpesvirus type 8‐positive solid lymphomas: a tissue‐based variant of primary effusion lymphoma. J Mol Diagn 2005;7(1):1727.Cross Ref linkPubmed link
  • 86  Safai B, Mike V, Giraldo G, Beth E, Good RA. Association of Kaposi's sarcoma with second primary malignancies: possible etiopathogenic implications. Cancer 1980;45(6):14729.Cross Ref linkPubmed link
  • 87  Engels EA, Pittaluga S, Whitby D, et al. Immunoblastic lymphoma in persons with AIDS‐associated Kaposi's sarcoma: a role for Kaposi's sarcoma‐associated herpesvirus. Mod Pathol 2003;16(5):4249.Cross Ref linkPubmed link
  • 88  Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma‐associated herpesvirus‐like DNA sequences in multicentric Castleman's disease. Blood 1995;86(4):127680.Pubmed link
  • 89  Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma‐associated herpesvirus‐like DNA sequences in AIDS‐related body‐cavity‐based lymphomas. N Engl J Med 1995;332(18):118691.Cross Ref linkPubmed link
  • 90  Lemlich G, Schwam L, Lebwohl M. Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty‐four cases. J Am Acad Dermatol 1987;16(2 Pt 1):31925.Cross Ref linkPubmed link
  • 91  Kolios G, Kaloterakis A, Filiotou A, Nakos A, Hadziyannis S. Gastroscopic findings in Mediterranean Kaposi's sarcoma (non‐AIDS). Gastrointest Endosc 1995;42(4):3369.Cross Ref linkPubmed link
  • 92  Rosella M, Masotti A, Cottoni F. Endoscopic examination in Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2000;14(3):2256.Cross Ref linkPubmed link
  • 93  Templeton AC. Studies in Kaposi's sarcoma. Postmortem findings and disease patterns in women. Cancer 1972;30(3):85467.Cross Ref linkPubmed link
  • 94  Anthony CW. Visceral Kaposi's sarcoma. Arch Pathol 1960;70:7406.Pubmed link
  • 95  Reed WB, Kamath M, Weiss L. Kaposi sarcoma, with emphasis on the internal manifestations. Arch Dermatol 1974;110(1):11518.Cross Ref linkPubmed link
  • 96  Krayem AB, Abdullah LS, Raweily EA, et al. The diagnostic challenge of pulmonary Kaposi's sarcoma with pulmonary tuberculosis in a renal transplant recipient: a case report. Transplantation 2001;71(10):148891.Cross Ref linkPubmed link
  • 97  Krayem AB, Wali SO, Samman YS. The diagnostic challenge and management of pulmonary Kaposi's sarcoma in renal transplant recipients. Saudi Med J 2001;22(12):10614.Pubmed link
  • 98  Neff R, Kremer S, Voutsinas L, Waxman M, Mitty W, Jr. Primary Kaposi's sarcoma of the ileum presenting as massive rectal bleeding. Am J Gastroenterol 1987;82(3):2767.Pubmed link
  • 99  Regnier‐Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013;68(2):31331.Cross Ref linkPubmed link
  • 100  Yildiz F, Genc M, Akyurek S, et al. Radiotherapy in the management of Kaposi's sarcoma: comparison of 8 Gy versus 6 Gy. J Natl Med Assoc 2006;98(7):11369.Pubmed link
  • 101  Brambilla L, Bellinvia M, Tourlaki A, Scoppio B, Gaiani F, Boneschi V. Intralesional vincristine as first‐line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol 2010;162(4):8549.Cross Ref linkPubmed link
  • 102  Ghyka G, Alecu M, Halalau F, Coman G. Intralesional human leukocyte interferon treatment alone or associated with IL‐2 in non‐AIDS related Kaposi's sarcoma. J Dermatol 1992;19(1):359.Cross Ref linkPubmed link
  • 103  Trattner A, Reizis Z, David M, Ingber A, Hagler J, Sandbank M. The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma. Br J Dermatol 1993;129(5):5903.Cross Ref linkPubmed link
  • 104  Celestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV‐negative Kaposi's sarcoma skin lesions: a phase I to II, open‐label trial in 17 patients. J Am Acad Dermatol 2008;58(4):58591.Cross Ref linkPubmed link
  • 105  Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. Aids 2008;22(8):93745.Cross Ref linkPubmed link
  • 106  Guenova E, Metzler G, Hoetzenecker W, Berneburg M, Rocken M. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 2008;144(5):6923.Pubmed link
  • 107  Yilmaz R, Akoglu H, Kirkpantur A, et al. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient. Ren Fail 2007;29(1):1035.Cross Ref linkPubmed link
  • 108  Boratynska M, Zmonarski SC, Klinger M. Reccurence of Kaposi's sarcoma after increased exposure to sirolimus. Int Immunopharmacol 2006;6(13–14):201822.Cross Ref linkPubmed link
  • 109  Konstantinopoulos PA, Sullivan RJ, Karamouzis MV, Dezube BJ. Investigational agents for treatment of AIDS‐related Kaposi's sarcoma. Expert Opin Invest Drugs 2007;16(4):495504.Cross Ref link
  • 110  Campistol JM, Gutierrez‐Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004;77(5):7602.Cross Ref linkPubmed link
  • 111  Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. Cancer 1994;74(10):28738.Cross Ref linkPubmed link
  • 112  Brambilla L, Miedico A, Ferrucci S, et al. Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2006;20(9):10904.Cross Ref linkPubmed link
  • 113  Brambilla L, Boneschi V, Fossati S, Melotti E, Clerici M. Oral etoposide for Kaposi's Mediterranean sarcoma. Dermatologica 1988;177(6):3659.Cross Ref linkPubmed link
  • 114  Brambilla L, Romanelli A, Bellinvia M, et al. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br J Dermatol 2008;158(6):133944.Cross Ref linkPubmed link
  • 115  Brambilla L, Boneschi V, Fossati S, Ferrucci S, Finzi AF. Vinorelbine therapy for Kaposi's sarcoma in a kidney transplant patient. Dermatology 1997;194(3):2813.Cross Ref linkPubmed link
  • 116  Kreuter A, Rasokat H, Klouche M, et al. Liposomal pegylated doxorubicin versus low‐dose recombinant interferon alfa‐2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest 2005;23(8):6539.Cross Ref linkPubmed link
  • 117  Di Lorenzo G, Di Trolio R, Montesarchio V, et al. Pegylated liposomal doxorubicin as second‐line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Cancer 2008;112(5):114752.Cross Ref linkPubmed link
  • 118  Di Lorenzo G, Kreuter A, Di Trolio R, et al. Activity and safety of pegylated liposomal doxorubicin as first‐line therapy in the treatment of non‐visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol 2008;128(6):157880.Cross Ref linkPubmed link
  • 119  Di Trolio R, Di Lorenzo G, Delfino M, De Placido S. Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review. Int J Immunopathol Pharmacol 2006;19(2):25363.Pubmed link
  • 120  Potouridou I, Korfitis C, Ioannidou D, et al. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities. Br J Dermatol 2008;158(2):4312.Cross Ref linkPubmed link
  • 121  Zidan J, Robenstein W, Abzah A, Taman S. Treatment of Kaposi's sarcoma with vinblastine in patients with disseminated dermal disease. Isr Med Assoc J 2001;3(4):2513.Pubmed link
  • 122  Fardet L, Stoebner PE, Bachelez H, et al. Treatment with taxanes of refractory or life‐threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer 2006;106(8):17859.Cross Ref linkPubmed link
  • 123  Basciani S, Vona R, Matarrese P, et al. Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. FEBS Lett 2007;581(30):5897903.Cross Ref linkPubmed link
  • 124  Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib‐induced regression of AIDS‐related Kaposi's sarcoma. J Clin Oncol 2005;23(5):9829.Cross Ref linkPubmed link
  • 125  Ardavanis A, Doufexis D, Kountourakis P, Rigatos G. A Kaposi's sarcoma complete clinical response after sorafenib administration. Ann Oncol 2008;19(9):16589.Cross Ref linkPubmed link